Molecular Imaging of Targeted Therapies with Positron Emission Tomography: the Visualization of Personalized Cancer Care

Overview

Journal Cell Oncol (Dordr)

Publisher Springer

Date 2014 Sep 25

PMID 25248503

Citations 15

Authors

Lemonitsa H Mammatas

Henk M W Verheul

N Harry Hendrikse

Maqsood Yaqub

Adriaan A Lammertsma

C Willemien Menke-van der Houven van Oordt

Affiliations

Soon will be listed here.

Abstract

Introduction: Molecular imaging has been defined as the visualization, characterization and measurement of biological processes at the molecular and cellular level in humans and other living systems. In oncology it enables to visualize (part of) the functional behaviour of tumour cells, in contrast to anatomical imaging that focuses on the size and location of malignant lesions. Available molecular imaging techniques include single photon emission computed tomography (SPECT), positron emission tomography (PET) and optical imaging. In PET, a radiotracer consisting of a positron emitting radionuclide attached to the biologically active molecule of interest is administrated to the patient. Several approaches have been undertaken to use PET for the improvement of personalized cancer care. For example, a variety of radiolabelled ligands have been investigated for intratumoural target identification and radiolabelled drugs have been developed for direct visualization of the biodistibution in vivo, including intratumoural therapy uptake. First indications of the clinical value of PET for target identification and response prediction in oncology have been reported. This new imaging approach is rapidly developing, but uniformity of scanning processes, standardized methods for outcome evaluation and implementation in daily clinical practice are still in progress. In this review we discuss the available literature on molecular imaging with PET for personalized targeted treatment strategies.

Conclusion: Molecular imaging with radiolabelled targeted anticancer drugs has great potential for the improvement of personalized cancer care. The non-invasive quantification of drug accumulation in tumours and normal tissues provides understanding of the biodistribution in relation to therapeutic and toxic effects.

Citing Articles

SPECT/CT imaging of EGFR-positive head and neck squamous cell carcinoma patient-derived xenografts with Pb-PSC-panitumumab in NRG mice.

Sarrami N, Nelson B, Leier S, Wilson J, Chan C, Meens J EJNMMI Radiopharm Chem. 2024; 9(1):79.

PMID: 39589608 PMC: 11599518. DOI: 10.1186/s41181-024-00313-8.

Synthesis and Evaluation of [Cu]Cu-NOTA-HFn for PET Imaging of Transferrin Receptor 1 Expression in Nasopharyngeal Carcinoma.

Shen Y, Zhou R, Bi L, Huang G, Yang M, Li Z ACS Omega. 2024; 9(15):17423-17431.

PMID: 38645324 PMC: 11024937. DOI: 10.1021/acsomega.4c00187.

p53 stabilisation potentiates [Lu]Lu-DOTATATE treatment in neuroblastoma xenografts.

Berglund H, Salomonsson S, Mohajershojai T, Gago F, Lane D, Nestor M Eur J Nucl Med Mol Imaging. 2023; 51(3):768-778.

PMID: 37823909 PMC: 10796565. DOI: 10.1007/s00259-023-06462-3.

Application of iron oxide nanoparticles in the diagnosis and treatment of leukemia.

Wang Y, Yang Y, Zheng X, Shi J, Zhong L, Duan X Front Pharmacol. 2023; 14:1177068.

PMID: 37063276 PMC: 10097929. DOI: 10.3389/fphar.2023.1177068.

Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer.

Cuda T, He Y, Kryza T, Khan T, Tse B, Sokolowski K Contrast Media Mol Imaging. 2021; 2021:3153278.

PMID: 34621145 PMC: 8455202. DOI: 10.1155/2021/3153278.

References

Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J . Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-19. PMC: 3724529. DOI: 10.1056/NEJMoa1002011. View

Verhagen A, Studeny M, Luurtsema G, Visser G, De Goeij C, SLUYSER M . Metabolism of a [18F]fluorine labeled progestin (21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone) in humans: a clue for future investigations. Nucl Med Biol. 1994; 21(7):941-52. DOI: 10.1016/0969-8051(94)90083-3. View

Chang A, Sohn R, Lu Z, Arbeit J, Lapi S . Detection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPET. PLoS One. 2013; 8(3):e58949. PMC: 3597567. DOI: 10.1371/journal.pone.0058949. View

Gao M, Lola C, Wang M, Miller K, Sledge G, Zheng Q . Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer. Bioorg Med Chem Lett. 2011; 21(11):3222-6. DOI: 10.1016/j.bmcl.2011.04.049. View

Mankoff D . A definition of molecular imaging. J Nucl Med. 2007; 48(6):18N, 21N. View

Cai W, Chen K, He L, Cao Q, Koong A, Chen X . Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging. 2007; 34(6):850-8. DOI: 10.1007/s00259-006-0361-6. View

Van Den Bossche B, Van de Wiele C . Receptor imaging in oncology by means of nuclear medicine: current status. J Clin Oncol. 2004; 22(17):3593-607. DOI: 10.1200/JCO.2004.10.216. View

Nayak T, Garmestani K, Baidoo K, Milenic D, Brechbiel M . Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma. J Nucl Med. 2010; 51(6):942-50. PMC: 2892806. DOI: 10.2967/jnumed.109.071290. View

Miao Z, Ren G, Liu H, Jiang L, Cheng Z . Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein. Bioconjug Chem. 2010; 21(5):947-54. DOI: 10.1021/bc900515p. View

10.

Artale S, Sartore-Bianchi A, Veronese S, Gambi V, Sarnataro C, Gambacorta M . Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol. 2008; 26(25):4217-9. DOI: 10.1200/JCO.2008.18.7286. View

11.

Narang V, Fraga C, Kumar N, Shen J, Throm S, Stewart C . Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. Am J Physiol Cell Physiol. 2008; 295(2):C440-50. PMC: 2518425. DOI: 10.1152/ajpcell.00491.2007. View

12.

Wagner C, Langer O . Approaches using molecular imaging technology -- use of PET in clinical microdose studies. Adv Drug Deliv Rev. 2010; 63(7):539-46. PMC: 3691790. DOI: 10.1016/j.addr.2010.09.011. View

13.

Gaykema S, Brouwers A, Lub-de Hooge M, Pleijhuis R, Timmer-Bosscha H, Pot L . 89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med. 2013; 54(7):1014-8. DOI: 10.2967/jnumed.112.117218. View

14.

Nagengast W, de Korte M, Oude Munnink T, Timmer-Bosscha H, den Dunnen W, Hollema H . 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med. 2010; 51(5):761-7. DOI: 10.2967/jnumed.109.071043. View

15.

Seimbille Y, Benard F, Rousseau J, Pepin E, Aliaga A, Tessier G . Impact on estrogen receptor binding and target tissue uptake of [18F]fluorine substitution at the 16alpha-position of fulvestrant (faslodex; ICI 182,780). Nucl Med Biol. 2004; 31(6):691-8. DOI: 10.1016/j.nucmedbio.2004.02.010. View

16.

Xavier C, Vaneycken I, DHuyvetter M, Heemskerk J, Keyaerts M, Vincke C . Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med. 2013; 54(5):776-84. DOI: 10.2967/jnumed.112.111021. View

17.

Su H, Seimbille Y, Ferl G, Bodenstein C, Fueger B, Kim K . Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging. 2008; 35(6):1089-99. DOI: 10.1007/s00259-007-0636-6. View

18.

Mankoff D, Link J, Linden H, Sundararajan L, Krohn K . Tumor receptor imaging. J Nucl Med. 2008; 49 Suppl 2:149S-63S. DOI: 10.2967/jnumed.107.045963. View

19.

Adams M, Turkington T, Wilson J, Wong T . A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010; 195(2):310-20. DOI: 10.2214/AJR.10.4923. View

20.

Liedtke C, Broglio K, Moulder S, Hsu L, Kau S, Symmans W . Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009; 20(12):1953-8. PMC: 2791352. DOI: 10.1093/annonc/mdp263. View